Market closed

Geron/$GERN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Ticker

$GERN

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Foster City, United States

Employees

141

Website

www.geron.com

Geron Metrics

BasicAdvanced

$1.8B

-

-$0.32

0.51 -

Price and volume

Market cap

$1.8B

Beta

0.51

52-week high

$5.34

52-week low

$1.64

Average daily volume

12M

Financial strength

Current ratio

2.886

Quick ratio

2.477

Long term debt to equity

5.041

Total debt to equity

5.041

Interest coverage (TTM)

-17.16%

Management effectiveness

Return on assets (TTM)

-30.30%

Return on equity (TTM)

-69.03%

Valuation

Price to revenue (TTM)

63.56

Price to book

6.15

Price to tangible book (TTM)

6.15

Price to free cash flow (TTM)

-8.655

Growth

Revenue change (TTM)

9,199.68%

Earnings per share change (TTM)

-5.33%

3-year revenue growth (CAGR)

318.22%

3-year earnings per share growth (CAGR)

-1.25%

What the Analysts think about Geron

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Geron stock.

Geron Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Geron Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Geron News

AllArticlesVideos

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·4 weeks ago

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

Business Wire·1 month ago

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GERN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Geron stock?

Geron (GERN) has a market cap of $1.8B as of January 15, 2025.

What is the P/E ratio for Geron stock?

The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of January 15, 2025.

Does Geron stock pay dividends?

No, Geron (GERN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Geron dividend payment date?

Geron (GERN) stock does not pay dividends to its shareholders.

What is the beta indicator for Geron?

Geron (GERN) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.